Pre-Market Technical Scan on Biotech Equities -- Spectrum Pharma, Jazz Pharma, Intra-Cellular Therapies, and Dermira

Wednesday, December 13, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, December 13, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely

information, WallStEquities.com has issued free tailored Stock Review on SPPI, JAZZ, ITCI, and DERM which is a click away at http://www.wallstequities.com/registration . On Tuesday, December 12, 2017, US markets saw four out
of nine sectors finishing the day in red, three in green, and two in neutral territory. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 6,862.32, down 0.19%; the Dow Jones Industrial Average edged 0.49% higher, to finish at 24,504.80; and the S&P 500 closed at 2,664.11, up 0.15%. This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), Intra-Cellular Therapies Inc. (NASDAQ: ITCI), and Dermira Inc. (NASDAQ: DERM). Get your free stock reports on these stocks by registering now on Wall St. Equities at:

http://www.wallstequities.com/registration

Spectrum Pharmaceuticals 

On Tuesday, shares in Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc. recorded a trading volume of 886,128 shares. The stock ended the session 1.76% higher at $18.53. The Company's shares have gained 83.65% over the previous three months, 317.34% in the past twelve months, and 318.28% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.90% and 81.92%, respectively. Moreover, shares of Spectrum Pharma, which develops and commercializes oncology and hematology drug products, have a Relative Strength Index (RSI) of 51.83. Get started with a complimentary subscription and access to the free report on SPPI at:

http://www.wallstequities.com/registration/?symbol=SPPI

Jazz Pharmaceuticals 

Dublin, Ireland headquartered Jazz Pharmaceuticals PLC's stock closed the day 0.39% higher at $140.55 with a total trading volume of 320,684 shares. The Company's shares have advanced 36.85% over the last twelve months and 28.91% since the start of this year. The stock is trading above its 50-day moving averages by 0.69%. Additionally, shares of Jazz Pharma, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, have an RSI of 56.10.

On December 05th, 2017, research firm Mizuho reiterated its 'Neutral' rating on the Company's stock with an increase of the target price from $144 a share to $150 a share. Free research on JAZZ can be accessed at:

http://www.wallstequities.com/registration/?symbol=JAZZ

Intra-Cellular Therapies 

Shares in New York headquartered Intra-Cellular Therapies Inc. recorded a trading volume of 351,376 shares. The stock ended yesterday's trading session 0.07% lower at $14.86. The Company's shares have advanced 0.47% in the past month. The stock is trading above its 200-day moving average by 6.65%. Furthermore, shares of Intra-Cellular Therapies, which engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease, have an RSI of 44.45. Sign up today for the free research report on ITCI at:

http://www.wallstequities.com/registration/?symbol=ITCI

Dermira 

Menlo Park, California headquartered Dermira Inc.'s stock finished Tuesday's session 1.96% higher at $27.05 with a total trading volume of 614,470 shares, which was above their three months average volume of 484.42 thousand shares. The Company's shares have advanced 9.03% in the last month. The stock is trading above its 50-day moving average by 3.12%. Additionally, shares of Dermira, which engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the US, have an RSI of 60.28.

On December 12th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $43 a share to $39 a share. Wall St. Equities' research coverage also includes the downloadable free report on DERM at:

http://www.wallstequities.com/registration/?symbol=DERM

--

Wall St. Equities: 

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@wallstequities.com Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store